Cancer Epidemiology
Volume 34, Issue 4 , Pages 359-367 , August 2010

Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007

  • R. Kvåle

      Affiliations

    • Department of Clinical and Registry-based research, The Cancer Registry of Norway, Oslo, Norway
    • Corresponding Author InformationCorresponding author at: The Cancer Registry of Norway, Post-box 5313 Majorstuen, 0304 Oslo, Norway. Tel.: +47 22451300, fax: +47 22451370.
    • ,
  • B. Møller

      Affiliations

    • Department of Clinical and Registry-based research, The Cancer Registry of Norway, Oslo, Norway
    • ,
  • A. Angelsen

      Affiliations

    • Department of Urology, St Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway
    • ,
  • O. Dahl

      Affiliations

    • Section of Oncology, Institute of Medicine, University of Bergen and Department of Oncology, Haukeland University Hospital, Bergen, Norway
    • ,
  • S.D. Fosså

      Affiliations

    • Department of Radiation Therapy and Medical Oncology, Rikshospitalet Medical Center, Oslo, Norway
    • University of Oslo, Medical Faculty, Oslo, Norway
    • ,
  • O.J. Halvorsen

      Affiliations

    • Department of Pathology, The Gade Institute, Haukeland University Hospital, Bergen, Norway
    • ,
  • L. Hoem

      Affiliations

    • Department of Urology, Nordland Central Hospital, Bodø, Norway
    • ,
  • A. Solberg

      Affiliations

    • Department of Radiation Therapy and Medical Oncology, St Olavs Hospital, University Hospital of Trondheim, Trondheim, Norway
    • ,
  • R. Wahlqvist

      Affiliations

    • Oslo Urological University Clinic, Oslo University Hospital, Aker, University of Oslo, Norway
    • ,
  • F. Bray

      Affiliations

    • Department of Clinical and Registry-based research, The Cancer Registry of Norway, Oslo, Norway
    • Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Norway

,Accepted 28 April 2010.

References 

  1. Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99:1881–1887
  2. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–1984
  3. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308
  4. Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, et al. Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol; in press.
  5. Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the “PSA ERA”. Int J Cancer. 2001;92:893–898
  6. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: An overwiew of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218–1231
  7. Fall K, Stromberg F, Rosell J, Andren O, Varenhorst E. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42:352–357
  8. Grulich AE, Swerdlow AJ, dos SSI, Beral V. Is the apparent rise in cancer mortality in the elderly real? Analysis of changes in certification and coding of cause of death in England and Wales, 1970–1990. Int J Cancer. 1995;63:164–168
  9. Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint Å, et al. NORDCAN:Cancer Incidence, Mortality, Prevalence and Prediction in the Nordic Countries, Version 3.5. Association of the Nordic Cancer Registries. Danish Cancer Society. (http://www.ancr.nu).
  10. National Cancer Institute.Statistical Research and Applications Branch, Joinpoint Regression Program, Version 3.3; National Cancer Institute, Bethesda. Aivailable at: http://srab.cancer.gov/joinpoint/.
  11. Armitage P, Berry G. Statistical methods in medical research. second ed.. Oxford: Blackwell Scientific Publications; 1987;
  12. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual percentage change in trends analysis. Stat Med. 2009;29:3670–3682
  13. Servoll E, Halvorsen OJ, Haukaas S, Høisaeter PA. Radical retropubic prostatectomy: our experience with the first 54 patients. Scand J Urol Nephrol. 1992;26:231–234
  14. Haukaas S, Skaarland E, Halvorsen OJ, Stensland E, Farstad M. [Prostate-specific antigen. A new biological serum marker for the adenocarcinoma of the prostate]. Tidsskr Nor Laegeforen. 1990;110:2990–2993
  15. Karlsdóttir A, Paul ML, Wentzel-Larsen T, Johannessen DC, Bakke A, Øgreid P, et al. Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncol. 2006;45:454–462
  16. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–916
  17. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med. 2009;360:1320–1328
  18. Hernes E, Kyrdalen A, Kvåle R, Hem E, Klepp O, Axcrona K, et al. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU Int. 2009;
  19. Myhre K, Fosså SD, Bjerklund Johansen T, Hoisether PA, Vatten L. Screening for prostatakreft. SMM-rapport nr. 3/1999,1-31. Oslo, Senter for medisinsk metodevurdering.
  20. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  21. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  22. Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)—Section Rotterdam. A comparison of two rounds of screening. Eur Urol. 2007;52:89–97
  23. Kvåle R, Skarre E, Tønne A, Kyrdalen AE, Norstein J, Angelsen A, et al. [Curative treatment of prostatic cancer in Norway in 1998 and 2001]. Tidsskr Nor Laegeforen. 2006;126:912–916
  24. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  25. Pilepich MV, Krall JM, al Sarraf M, John MJ, Doggett RL, Sause WT, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45:616–623
  26. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  27. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  28. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2008;
  29. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002;167:1664–1669
  30. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004;5:101–106
  31. Metcalfe C, Tilling K, Davis M, Lane JA, Martin RM, Kynaston H, et al. Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. Br J Cancer. 2009;101:390–394
  32. Bratt O. Watching the face of Janus—active surveillance as a strategy to reduce overtreatment for localised prostate cancer. Eur Urol. 2006;50:410–412
  33. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1–88
  34. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85
  35. Haldorsen T, Tynes T. Cancer in the Sami population of North Norway, 1970–1997. Eur J Cancer Prev. 2005;14:63–68
  36. Tulinius H, Storm HH, Pukkala E, Andersen A, Ericsson J. Cancer in the Nordic countries, 1981–86. A joint publication of the five Nordic Cancer Registries. APMIS Suppl. 1992;31:1–194
  37. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17:88–94
  38. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003;24:453–459
  39. Murtola TJ, Visakorpi T, Lahtela J, Syvala H, Tammela TL. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol. 2008;5:376–387

PII: S1877-7821(10)00079-2

doi: 10.1016/j.canep.2010.04.017

Cancer Epidemiology
Volume 34, Issue 4 , Pages 359-367 , August 2010

Article Tools

* Image Usage & Resolution